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Background: Atherogenesis represents an active inflammatory process with leucocytes playing a major role. An elevated
white blood cell count has been shown to be predictive of death in coronary artery disease patients. The aim of this study
was to examine the predictive ability of neutrophil count and neutrophil/lymphocyte ratio for predicting survival in
patients with critical lower limb ischemia (CLI).
Methods: All patients admitted to a single vascular unit with CCLI were identified prospectively over a 2-year period
starting from January 2005. Patient demographics, clinical history, comorbidity, and risk factors for peripheral vascular
disease were documented. The white blood count and differential cell count at admission was recorded. Overall, patient
mortality was studied as the primary outcome.
Results: One hundred forty-nine patients were identified, with a median age of 72 years (Interquartile range [IQR],
65.7-81). A neutrophil-lymphocyte ratio (NLR) of >5.25 was taken as the cutoff, based upon the receiver-operating-
characteristic.The median follow up was 8.7 months (IQR, 3.1-16). During the follow-up period, there have been 62
deaths (43.4%). An elevated neutrophil/lymphocyte ratio and a high troponin level (>0.1) were found to be the only two
factors independently associated with shorter survival onmultivariate analysis using the Cox proportional hazards model.
Conclusions: This study suggests that an elevated NLR can identify a poor-risk subset of patients among those being
treated for critical limb ischemia. This simple, inexpensive test may, therefore, add to risk stratification of these high-risk
patients. ( J Vasc Surg 2010;52:632-6.)Adverse cardiovascular events are a significant cause of
major morbidity and mortality in the perioperative period.
Patients with chronic critical limb ischemia (CLI) have a
high incidence of coronary heart disease (CHD), with
autopsy studies showing that 90% of patients have ad-
vanced coronary atherosclerosis.1-3 The 1-year mortality
rate has been reported to be 26% and as high as 75% at 10
years.4 Risk stratification for patients who present with CLI
has become increasingly important in order to improve
clinical decision making and to determine the most appro-
priate therapy for individual patients, by identifying not
only high-risk patients but also determining which patients
would benefit most from newer, less-invasive, or potentially
less-durable therapies. Identifying patients at risk before an
operation is also useful if used to modify the perioperative
management and reduce complication rates.
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632In recent years, it has been noted that atherosclerosis
represents an active inflammatory process in which leuco-
cytes play a major role. The white blood cell (WBC) count
and its subtypes have been found to correlate with outcome
in stable and unstable coronary syndromes, including ST-
elevationmyocardial infarction (MI) and non–ST-elevation
MI.5-8 The neutrophil/lymphocyte ratio (NLR) has
emerged as a prognostic marker and with a proinflamma-
tory state being associated with worse outcomes in cardiac
disease as well as in oncologic surgery.9-11
This study was conducted to investigate the role of
admission NLR in predicting all-cause mortality in patients
with CLI who underwent therapeutic intervention.
PATIENTS AND METHODS
All patients admitted with CLI at a single university
teaching hospital were entered into this prospective study
over a 2-year period. CLI was defined using the following
criteria for diagnosis: more than 2 weeks of recurrent foot
pain at rest that requires regular use of opiate analgesics and
is associated with an ankle systolic pressure of 50mmHg or
less, or a toe systolic pressure of 30 mm Hg or less, or a
nonhealing wound or gangrene of the foot or toes (Ruth-
erford categories 4 and 5). The protocol was approved by
the institutional review board.
Demographic characteristics, medical histories, labora-
tory studies (includingWBC counts and automated periph-
eral differential counts), and outcomes data were collected
by the research team using a standardized database. Any
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documented as follows: primary surgery (limb salvage),
primary surgery (amputation), radiological, or a combined
procedure. Patients with evidence of acute limb ischemia,
infected ischemic ulcers, or current symptomatic or unsta-
ble coronary disease (n  3) were excluded from outcome
analysis. All-cause mortality following admission was the
primary outcome variable.
Patients were followed up in outpatient clinics follow-
ing discharge. For patients who died while an in-patient,
hospital records and autopsy results were retrieved and
reviewed. Mortality was recorded from the hospital Patient
Administration System. For patients who died in the com-
munity, general practitioners were approached to ascertain
the cause of death. A secondary endpoint of cardiac-specific
mortality was also recorded from the death certificate (MI,
arrhythmias, congestive cardiac failure) and by reviewing
the hospital notes.
Statistical analysis. The effect of NLR on outcome
was studied by constructing a receiver operating character-
istic (ROC) curve with all-cause mortality as the primary
variable. (Fig 1). Analysis was performed using SPSS ver-
sion 11.0.0 (SPSS Inc, Chicago, IL). The chi-square test
was used to perform univariate analysis for categorical
variables and Mann-Whitney U test for continuous vari-
ables. Results are presented as median with interquartile
range unless otherwise specified. Survival analysis was con-
ducted using Kaplan-Meier survival curves, and differences
were compared using the log-rank test. Cox regression
analysis of all variables was conducted in a stepwise fashion.
A P value  .05 was considered statistically significant.
RESULTS
One hundred fifty-one patients met the inclusion crite-
ria for analysis during the study period. Two patients were
excluded because of insufficient data at admission. The
median age was 72 years (interquartile range [IQR],
65.7-81 years) and median follow-up was 8.7 months
(IQR, 3.1-16 months).
Selection of a cutoff for the NLR. An analysis of the
NLR with respect to mortality was conducted using tertiles
of existing data (ie, using cutoffs of NLR 3.4, NLR
between 3.4 and 6.8, and an NLR 6.8). This calculation
provided fairly good discriminant value (P .022; Fig 1A).
While NLR appeared to affect the outcome in a con-
tinuous fashion, we chose to use a single cutoff point to
better inform clinical practice. An ROC was constructed to
study the effect of NLR with all-cause mortality as the
primary variable (Fig 1B). The ROC characteristic had a
c-statistic of 0.69, and a value of NLR 5.25 was selected
as a cutoff, to maximize sensitivity and specificity. A sensi-
tivity of 69% and a specificity of 71% were obtained for the
final model. Sixty-five (43.9%) patients had a neutrophil
lymphocyte ratio 5.25 at admission.
The univariate analysis of the two groups based on
factors studied is shown in Table I. Tissue loss at presenta-
tion was comparable between groups. Older patients were
significantly more likely to have an elevated NLR, with themean age in the high NLR group versus low NLR group
being 76.1  10.1 years versus 70.6  10.7 years, respec-
tively (P  .03). The incidence of diabetes and hyperten-
sion were significantly higher in the low NLR group, while
elevated troponin levels (0.1) were more commonly
found in the high NLR group. Statin use differed between
groups (32.5% in the low NLR group vs 18.8% in the high
NLR group; P  .06). No trends could be demonstrated
for the other variables on univariate analysis (Table I). The
absolute neutrophil and lymphocyte counts for the low and
high NLR groups were significantly different (neutrophil
counts 5.9  2.1 vs 10.3  4.5, P  .001; lymphocyte
Fig 1. (A) Kaplan-Meier curves for neutrophil/lymphocyte ratio
(NLR) using tertiles (P  .002). (B) A receiver operating character-
istic (ROC) for neutrophil-lymphocyte ratio versus mortality.counts 2.3  2.4 vs 1.1  0.5, P  .001).
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Table II. There was a nonsignificantly higher incidence of
major amputations in the elevated NLR group (18.1% vs
13.2%; P  .5). A higher number of patients with lower
NLR underwent vascular reconstructive surgery (25.1% vs
9.2%; P .5). There was no difference in the failure rates of
surgical revascularization in both groups (n 2 and n 3;
P  .32). There was no significant difference in the rates
of nonsurgical or conservative management between the
groups.
There were 62 deaths during the course of the study.
Thirty-eight of these occurred within the elevated NLR
group, while 24mortalities occurred in the lowNLR group
(58.4% vs 28.6%; P  .001). Of the 20 deaths which were
specifically attributed to cardiac causes, seven (8.4% of the
cohort mortality) occurred in the lowNLR group, while 13
(19.5% of the cohort mortality) occurred in the high NLR
group (P .055). Median survival for the low NLR group
was not reached, while the median survival for the elevated
NLR group was 8.6 months (P .006 on log-rank survival
analysis; Fig 2).
Risk factors for mortality, including age 70 years, ele-
Table I. Univariate analysis of risk factors for patients
with critical ischemia
Variable
NLR
5.25
(n  83)
NLR
5.25
(n  66)
P
value
Age 70 years (86) 41 (49.3%) 45 (68.1%) .03
Diabetes (44) 36 (43.4%) 8 (12.1%) .001
Hypertension (83) 53 (63.8%) 30 (45.5%) .04
Previous myocardial
infarction (14) 11 (13.2%) 3 (4.5%) .5
Previous
cerebrovascular
accident (15) 11 (13.2%) 4 (6.1%) .18
Renal failure (8) 3 (3.6%) 5 (7.6%) 1
Smokers (103) 63 (75.9%) 40 (60.6%) .14
Troponin 0.1 (50) 19 (22.9%) 31 (41.9%) .003
Tissue loss at admission 16 (19.2%) 11 (16.7%) .8
Statin use 27 (32.5%) 12 (18.8%) .06
NLR, Neutrophil/lymphocyte ratio.
Figures are presented as n and percentage.
Renal failure, patients who were on dialysis at the time of assessment.
Table II. Analysis of procedures for elevated neutrophil/
lymphocyte ratio
NLR
5.25
(n  83)
NLR
5.25
(n  66)
P
value
Surgery (non amputation) 21 (25.3%) 6 (9.1%) .5
Angioplasty/stenting 21 (25.3%) 12 (18.2%) 1
Combined procedure 11 (13.2%) 5 (7.6%) 1
Major amputation 11 (13.2%) 12 (18.2%) .5
Minor amputation 6 (7.2%) 3 (4.5%)
Conservative/palliative 23 (27.7%) 27 (40.9%) .6
NLR, Neutrophil/lymphocyte ratio.vated troponin, history of stroke or previous MI, statin use,renal failure, elevatedNLR, and smokinghistory (at any time),
were included in a Cox regression model and analyzed in a
stepwise fashion. An elevated troponin, NLR  5.25, and
statin use pre-admission were independent predictive fac-
tors of all-cause mortality (hazard ratios [95% confidence
interval], 3.1 [1.6-5.6] and 2.3 [1.2-4.2], 0.2 [0.06-0.7]; P
 .001, .007, and .13, respectively; Table III).
DISCUSSION
This study demonstrates that an elevated NLR is asso-
ciated with higher mortality in patients with peripheral
arterial disease who present with CLI.
Patients suffering from peripheral artery disease bear a
considerable risk of MI, stroke, or cardiovascular death that
is directly related to the severity of disease.12 A mortality
rate of 43% is seen over a median follow-up time of 8.7
months, indicating a high risk of poor outcome, and this
underscores the need for additional parameters for risk
stratification.
Leukocytes of the monocyte-macrophage lineage have
a crucial pathophysiologic role in the development of ath-
Fig 2. Kaplan-Meier survival curve for neutrophil/lymphocyte
ratio (NLR), with a cutoff of 5.25.
Table III. Multivariate analysis of factors affecting
mortality in patients with critical limb ischemia
Hazard ratio
(95% confidence interval)
P
value
Elevated troponin 3.1 (1.6-5.6) .001
Neutrophil/lymphocyte ratio
5.25 2.3 (1.2-4.2) .007
Diabetes mellitus 0.5 (0.2-1.1) .1
Hypertension 1.4 (0.7-2.6) .4
Previous myocardial infarction 1.2 (0.4-3.8) .8
Renal failure 0.3 (0.05-3.7) .3
Statin use 0.2 (0.06-0.7) .013erosclerotic plaque and deposition of lipids therein. The
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total WBC count in the atherothrombotic process, seems
less clear. However, in most of the prospective cohort
studies that have provided information on differential WBC
count, the number of neutrophils correlated primarily and
consistently in a positive manner with the atherosclerotic
load and ischemic conditions.5,13-16
NLR has been found to be an independent predictor of
short-term mortality in patients with acute coronary dis-
ease. Neutrophils mediate inflammatory response by nu-
merous biochemical mechanisms, such as release of arachi-
donic acid metabolites and platelet-aggravating factors,
cytotoxic oxygen-derived free radicals, and hydrolytic en-
zymes such as myeloperoxidase, elastase, various hydrolytic
enzymes, and acid phosphatases. The neutrophil-lymphocyte
ratio therefore reflects both the neutrophilia of inflamma-
tion and the relative lymphopenia of cortisol-induced stress
response.17
It has been long known that myocardial injury (acute
MI) is followed by neutrophilia. Acute MI was excluded in
our primary analysis, but neutrophilia also could mark an
augmented, more chronic adaptive response to ischemia.
Neutrophilia may also indicate maladaptive processes: cir-
culating leukocyte-platelet aggregates appear in acute cor-
onary syndromes and may facilitate vascular plugging and
infarct extension.18,19 Additionally, a decrease in CD4
count and the CD4/CD8 ratio has been observed in
patients with acuteMI. Lymphocyte subsets such as CD4
are decreased after acute MI and are correlated with a low
ejection fraction and small infarct size. A decrease in the
number and suppressive function of naturally occurring
CD4CD25 regulatory T cells occurs in acute phases of
acute coronary syndromes, potentially due to oxidized
low-density lipoprotein.
NLR correlated well with other markers of a pro-
inflammatory state; recent studies of long-term outcome in
cardiac disease as well as oncologic resections have shown
associations of high C-reactive protein and elevated NLR
with poor long-term outcome.17,20 While the detrimental
effect of NLR on outcome is continuous, we chose to select
a single cutoff for clinical relevance. The overall accuracy of
an NLR cutoff of 5.25 in this dataset was 66.4%. This
cutoff correlated favorably to oncological and cardiac
data.10,17
This study was prospective in patient enrollment and
follow-up but was observational in nature and subject to
limitations, including selection bias. Most patients were on
antiplatelet therapy at the time of admission; however, just
39 (26.3%) were on statin therapy. Additionally, we could
not compare NLR with other inflammatory markers, such
as C-reactive protein, fibrinogen, or myeloperoxidase, be-
cause they were not routinely obtained in our study popu-
lation. Most of our patients had fairly aggressive correction
of anemia to maintain a hemoglobin of more than 80 g/L
in patients with no cardiac history, or 100 g/L in patients
with angina or proven cardiac disease, and this variable
could therefore not be analyzed in this study.On multivariate analysis, an elevated troponin, no sta-
tin use, and a high NLR were found to independently
predict mortality in this patient subgroup. The impact of an
elevated troponin on survival in patients with noncardiac
disease has been reported in hemodialysis patients21 and
CLI by several groups, including our own.22-24 Statins have
an important protective role for mortality and major car-
diovascular events (stroke, MI) in patients with peripheral
arterial disease; no specific protective effect has been dem-
onstrated in amputation-free survival in recent litera-
ture.25-29 The impact of an elevated NLR and its relation to
mortality has not been reported before in this patient set.
Risk-stratification models utilizing existing clinical data
exist and provide reasonable discrimination between good
and poor risk candidates for surgical intervention. Addi-
tional information provided on the patient’s proinflamma-
tory state by biomarkers may improve the discriminant
value of such scores.30,31 The NLR is an inexpensive and
readily available test. Patients undergoing vascular surgery
all undergo preoperative full blood counts. NLR is a readily
available biomarker that conveys important information
about the patient’s inflammatory activity. NLR can be
easily calculated from the differential WBC count, which is
routinely performed on admission and is universally avail-
able. Unlike many other inflammatory markers and bioas-
says, NLR is an inexpensive and readily available marker
that provides an additional level of risk stratification beyond
that provided by conventional risk scores in predicting
in-hospital and long-term mortality. Moreover, it is avail-
able preoperatively andmay be of use in counseling patients
with regard to treatment options and possible outcome. It
may be a useful prognostic indicator in CLI that does not
require any additional resources for routine use.
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